References
Diener H-C, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998 Nov; 56(5): 811–24
British National Formulary. No. 36. London: The Pharmaceutical Press, 1998 Sep
Lance JW. Current concepts of migraine pathogenesis. Neurology 1993 Jun; 43 Suppl. 3: S11–5
MacGregor A. Management of migraine in general practice. Prescriber 1998 Apr 19: 49, 53–4, 58, 60, 64, 66–7, 69
Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16: 264–9
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658–60
Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 13: 166–71
Andersson PG. Ergotism: the clinical picture. In: Diener HC, Wilkinson M, editors. Drug-induced headache. Berlin: Springer, 1988: 16–9
Maizels M, Scott B, Cohen W, et al. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA 1996 Jul 24–31; 276(4): 319–21
Rights and permissions
About this article
Cite this article
Tailor drug choice to headache severity in acute migraine attack. Drugs Ther. Perspect 13, 8–11 (1999). https://doi.org/10.2165/00042310-199913100-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199913100-00003